High-level expression of codon optimized foot-and-mouth disease virus complex epitopes and cholera toxin B subunit chimera in Hansenula polymorpha

2004 ◽  
Vol 315 (1) ◽  
pp. 235-239 ◽  
Author(s):  
Houhui Song ◽  
Li Zhou ◽  
Weihuan Fang ◽  
Yong Li ◽  
Xu Wang ◽  
...  
2013 ◽  
Vol 647 ◽  
pp. 424-429
Author(s):  
Xing Zhou Chen ◽  
Zhi Peng Xu ◽  
Xiao Ping Chen ◽  
Xi Hong Zhao ◽  
Qing Yang

Many genetically modified (GM) crops were used for production of plant-derived edible vaccines and other therapeutic recombinant products. However, GM crops resulted in the ecotoxicological risk of gene transfer because of pollen flow during the past 20 years. The most-commonly used eukaryotic model alga, Chlamydomonas reinhardtii has recently been shown the potential of decreasing this risk. Compared to GM crops, there is no risk of gene transfer because the alga culture can be deserved completely scrutiny under laboratory condition and it do not produce pollen. Recently, we had transformed the chloroplast of Chlamydomonas reinhardtii with two genes, CTB and CV1, which encode cholera toxin B subunit and chimeric antigen CV1 fused CTB with VP1 protein from foot and mouth disease virus (FDMV). The transgenic alga subculture were carried out under different selective conditions. The recombinant antigen in transgenic Chlamydomonas chloroplast was detected by western blotting in a period of subculture time. However, the PCR detection data demonstrated that transgene integrated with chloroplast genome would be lost in a special time when was connected with subculture condition. Although loss of transgenic fragment was an inevitable fate for the green alga, our research data showed the possibility that the presence of transgenic fragment was strictly regulated. Thus, the alga can be used for a safer platform for the production of recombinant product than GM crops.


Pharmaceutics ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 576
Author(s):  
Micaela A. Reeves ◽  
Joshua M. Royal ◽  
David A. Morris ◽  
Jessica M. Jurkiewicz ◽  
Nobuyuki Matoba ◽  
...  

Epicertin (EPT) is a recombinant variant of the cholera toxin B subunit, modified with a C-terminal KDEL endoplasmic reticulum retention motif. EPT has therapeutic potential for ulcerative colitis treatment. Previously, orally administered EPT demonstrated colon epithelial repair activity in dextran sodium sulfate (DSS)-induced acute and chronic colitis in mice. However, the oral dosing requires cumbersome pretreatment with sodium bicarbonate to conserve the acid-labile drug substance while transit through the stomach, hampering its facile application in chronic disease treatment. Here, we developed a solid oral formulation of EPT that circumvents degradation in gastric acid. EPT was spray-dried and packed into enteric-coated capsules to allow for pH-dependent release in the colon. A GM1-capture KDEL-detection ELISA and size-exclusion HPLC indicated that EPT powder maintains activity and structural stability for up to 9 months. Capsule disintegration tests showed that EPT remained encapsulated at pH 1 but was released over 180 min at pH 6.8, the approximate pH of the proximal colon. An acute DSS colitis study confirmed the therapeutic efficacy of encapsulated EPT in C57BL/6 mice upon oral administration without gastric acid neutralization pretreatment compared to vehicle-treated mice (p < 0.05). These results provide a foundation for an enteric-coated oral formulation of spray-dried EPT.


Sign in / Sign up

Export Citation Format

Share Document